FDA Orders Xolair Warnings
FDA Ordered Genentech Inc. To Add Warnings For Xolair. The U.S. Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair. The FDA said the boxed warning should emphasize Xolair (omalizumab) might cause anaphylaxis, including trouble breathing, chest tightness, dizziness, … [Read more...]
Genentech Issues Warning About Eye Drug Lucentis
Drug Lucentis May Increase The Risk Of Stroke. In a letter sent to 1,500 eye doctors, Genentech is warning that its macular degeneration drug, Lucentis, may increase the risk of stroke if administered in high doses. Approved a mere six months ago by the FDA, Lucentis has already generated nearly $400 million in sales for Genentech, … [Read more...]
Biogen, Genentech issue warning for Rituxan
Biogen Idec and Genetech Issued A Warning About The Drug Rituxan. Biogen Idec and Genentech have issued a warning to healthcare providers for their oncology drug Rituxan, advising them that the drug has been linked to the deaths of two lupus patients from a rare brain disease. According to an advisory sent out by the Food and Drug … [Read more...]
FDA issues alert on Genentech drug
Safety Information From Genentech Drug. Government health officials said Monday they are seeking additional safety information from Genentech Inc. on Rituxan following reports that two patients died while taking the drug, which is used to treat non-Hodgkins lymphoma and other conditions. The Food and Drug Administration said it … [Read more...]
FDA Adds New Warnings to Avastin
Avastin May Cause RPLS. Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the Food and Drug Administration said. The drug's label also now includes information about seven reports of patients who developed … [Read more...]
